Evidence map›Paper›PMID 35719960›Full record

ArticleFrontiers in oncology2022

A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED).

Thiru Prasanna, Laeeq Malik, Robert D McCuaig, Wen Juan Tu, Fan Wu, Pek Siew Lim, Abel H Y Tan, Jane E Dahlstrom, Philip Clingan, Eugene Moylan and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Thiru PrasannaAustralian National University (ANU) Medical School, Australian National University, Canberra, ACT, Australia.
Laeeq MalikAustralian National University (ANU) Medical School, Australian National University, Canberra, ACT, Australia.
Robert D McCuaigGene Regulation and Translational Medicine Laboratory, Infection and Inflammation Program, Queensland Institute of Medical Research Berghofer, Brisbane, QLD, Australia.
Wen Juan TuGene Regulation and Translational Medicine Laboratory, Infection and Inflammation Program, Queensland Institute of Medical Research Berghofer, Brisbane, QLD, Australia.
Fan WuFaculty of Science and Technology, University of Canberra, Bruce, ACT, Australia.
Pek Siew LimFaculty of Science and Technology, University of Canberra, Bruce, ACT, Australia.
Abel H Y TanFaculty of Science and Technology, University of Canberra, Bruce, ACT, Australia.
Jane E DahlstromAustralian National University (ANU) Medical School, Australian National University, Canberra, ACT, Australia.
Philip ClinganDepartment of Medical Oncology, Southern Medical Day Care Centre, Wollongong, NSW, Australia.
Eugene MoylanDepartment of Medical Oncology, Liverpool Hospital, Liverpool, NSW, Australia.
Jeremy ChrispEpiAxis Therapeutics Pty Ltd, Sydney, NSW, Australia.
David FullerEpiAxis Therapeutics Pty Ltd, Sydney, NSW, Australia.
Sudha RaoGene Regulation and Translational Medicine Laboratory, Infection and Inflammation Program, Queensland Institute of Medical Research Berghofer, Brisbane, QLD, Australia.
Desmond YipAustralian National University (ANU) Medical School, Australian National University, Canberra, ACT, Australia.
University of Canberra · AUQIMR Berghofer Medical Research Institute · AUAustralian National University · AUCanberra Hospital · AULiverpool Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Lysine-Specific Demethylase-1 (LSD1) is overexpressed in breast cancer cells and facilitate mesenchymal properties which may contribute to therapeutic resistance and cancer progression. The purpose of this study was to investigate the safety of combination, nab-paclitaxel and phenelzine, an irreversible LSD1 inhibitor in patients with metastatic breast cancer (mBC). Methods: Eligible patients with mBC were treated with nab-paclitaxel (100mg/m Results: The Optimum Biological Dose was established at 60mg of phenelzine daily in combination with nab-paclitaxel and considered as the recommended phase 2 dose. Most (95%) of adverse events were grade 1 or 2 with two grade 3 events being diarrhea and neutropenia at 45mg and 60mg phenelzine respectively, with no unexpected toxicity/deaths. Commonly reported toxicities were fatigue (n=4,50%), dizziness (n=6,75%), neutropenia (n=3,37.5%), peripheral neuropathy (n=3,37.5%), diarrhea (n=2,25%), and hallucination (n=2,25%). After a median follow up of 113 weeks, all patients showed disease progression on trial with 4 patients being alive at the time of data cut off, including one patient with triple negative breast cancer. Median progression-free survival was 34 weeks. Significant inhibition of LSD1 and suppression of mesenchymal markers in circulating tumor cells were noted. Conclusion: Phenelzine in combination with nab-paclitaxel was well tolerated, without any unexpected toxicities in patients with mBC and demonstrated evidence of antitumor activity. For the first time, this proof-of-concept study showed

Indexed as

breast cancercancer stem cellscirculating tumor cellslysine-specific demethylase 1metastasis

Identifiers

PMID35719960
PMCPMC9205212
OpenAlexW4281876459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.